Table 1 Clinical characteristics of patients at baseline
Patient chracteristicsa | SAGC group (n = 40) | GC group (n = 40) | pc |
|---|---|---|---|
Age (years), median | 62.5 (54.8, 68.3) | 59.5 (50.0, 66.3) | 0.244d |
CA199 (U/ml), median | 67.53 (21.8, 961.1) | 172.84 (20.1, 1428.0) | 0.796d |
Sex | 1.000e | ||
Female | 16 (40.0%) | 15 (37.5%) | |
Male | 24 (60.0%) | 25 (62.5%) | |
ECOGb performance status score | 0.494e | ||
0 | 2 (5.0%) | 0 (0%) | |
1 | 38 (95.0%) | 40(100.0%) | |
Primary tumor type | 0.643e | ||
Extrahepatic cholangiocarcinoma | 6 (15.0%) | 5 (12.5%) | |
Gallbladder carcinoma. | 11 (27.5%) | 8 (20.0%) | |
Intrahepatic cholangiocarcinoma | 23 (57.5%) | 27 (67.5%) | |
Extent of disease | 0.453e | ||
Initially unresectable | 31 (77.5%) | 27 (67.5%) | |
Recurrent | 9 (22.5%) | 13 (32.5%) | |
Metastases | |||
Liver | 26 (65.0%) | 26 (65.0%) | 1.000e |
Lung | 9 (22.5%) | 10 (25.0%) | 1.000e |
Bone | 3 (7.5%) | 8 (20.0%) | 0.194e |
Peritoneum | 9 (22.5%) | 8 (20.0%) | 1.000e |
Distant lymph node | 27 (67.5%) | 22 (55.0%) | 0.359e |
Hepatitis B Virus | 0.769e | ||
No | 34 (85.0%) | 32 (80.0%) | |
Yes | 6 (15.0%) | 8 (20.0%) | |
Previous history of surgery | 1.000e | ||
No | 26 (65.0%) | 25 (62.5%) | |
Yes | 14 (35.0%) | 15 (37.5%) | |
Previous adjuvant therapy | 1.000e | ||
No | 37 (92.5%) | 36 (90.0%) | |
Yes | 3 (7.5%) | 4 (10.0%) |
